Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · IEX Real-Time Price · USD
1.150
+0.020 (1.77%)
Jul 22, 2024, 10:14 AM EDT - Market open
Chemomab Therapeutics Employees
Chemomab Therapeutics had 20 employees as of December 31, 2021.
Employees
20
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$966,800
Market Cap
16.35M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2021 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| VBI Vaccines | 138 |
| Talis Biomedical | 99 |
| Lyra Therapeutics | 88 |
| Kindly MD | 65 |
| Sensei Biotherapeutics | 28 |
| Microbot Medical | 22 |
| Aeterna Zentaris | 12 |
| PharmaCyte Biotech | 2 |
CMMB News
- 6 weeks ago - Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference - GlobeNewsWire
- 2 months ago - Chemomab Therapeutics to Participate in Upcoming Scientific Conferences - GlobeNewsWire
- 2 months ago - Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - GlobeNewsWire
- 2 months ago - Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference - GlobeNewsWire
- 3 months ago - Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update - GlobeNewsWire
- 3 months ago - Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis - GlobeNewsWire
- 3 months ago - Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 - GlobeNewsWire